Overview

Ritonavir-boosted Lopinavir Monotherapy

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

To assess 48-week treatment responses, tolerability, and steady-state minimum plasma concentrations of ritonavir-boosted lopinavir monotherapy for salvage therapy in HIV-1 infected patients who failed antiretroviral regimens containing NRTI and NNRTI.

Phase:

Phase 3

Details

Lead Sponsor:

Bamrasnaradura Infectious Diseases Institute

Treatments:

Lopinavir
Reverse Transcriptase Inhibitors
Ritonavir